Clinical Factors Drive Choice of CDK4/6 Inhibitors for Hormone Receptor–Positive Breast Cancer
March 25th 2021As CDK4/6 inhibitors solidify their role as the treatment of choice for patients with hormone receptor–positive, HER2-negative breast cancer, an ongoing clinical challenge remains: distinguishing the appropriate agent.
Ki-67 Is Poised to Advance as a Biomarker in Early-Stage Breast Cancer
March 24th 2021Although Ki-67 is a commonly used measure of cellular proliferation in breast cancer tissue, its utility as a biomarker for helping to guide therapy decisions has been clouded by technical and clinical questions.
Investigators Focus Devimistat Study on Older Patients With AML
March 15th 2021Devimistat, a small molecule that targets enzymes involved in cancer cell metabolism, holds promise for older patients with relapsed or refractory acute myeloid leukemia who typically have a poor prognosis with standard-of-care chemotherapy
COVID-19 Spurs New Therapy Trends
March 12th 2021When the coronavirus disease 2019 pandemic started upending health care services throughout the United States a year ago, the oncology community moved quickly to develop guidance on selecting therapies and setting treatment schedules for many cancers to allow for less frequent in-patient visits to clinics and infusion centers.